

Special Issue

Major Breakthroughs in Diabetic Animal Model Research

Message from the Guest Editors

Diabetes mellitus is one of the most significant global health emergencies of the 21st century. According to a statistical analysis conducted by International Diabetes Federation in 2017, 451 million adult people have diabetes worldwide, and this number is expected to reach 693 million by 2045. WHO claimed that it will be the seventh leading cause of death worldwide in 2030. For these reasons, it is necessary to pay great attention to research on the processes occurring in the diabetic organism. Although research into the pathophysiology of this disease has been ongoing for more than 100 years, no effective and reliable therapy has yet been found. Animal models of individual types of diabetes played, and still play, a significant role in this research. The aim of this Special Issue is to collect the recent updates on the use of animal models in diabetes research, including, the description of hitherto undescribed pathological processes or new therapeutic options. We welcome original research and review articles.

Guest Editors

Dr. Magdalena Chottova Dvorakova

Biomedical Center, Faculty of Medicine in Pilsen, Charles University,
323 00 Pilsen, Czech Republic

Dr. Shashank Pandey

Biomedical Center, Faculty of Medicine in Pilsen, Charles University,
323 00 Pilsen, Czech Republic

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/163854

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).